Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 75.23 USD | +0.97% | -0.62% | -12.37% | |
| Nov. 29 | Amazon: 'Black Friday' and 're:Invent' support the stock | CF |
| Nov. 29 | Transcript : Gilead Sciences, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 09:00 AM | CI |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
75.23USD
Average target price
90.39USD
Spread / Average Target
+20.15%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -12.37% | 92 843 M $ | |
| +61.78% | 532 B $ | |
| +46.99% | 452 B $ | |
| -13.89% | 365 B $ | |
| -8.85% | 254 B $ | |
| -14.30% | 244 B $ | |
| -18.62% | 216 B $ | |
| +1.50% | 200 B $ | |
| -10.57% | 195 B $ | |
| -41.30% | 168 B $ |
- Stock
- Equities
- Stock Gilead Sciences, Inc. - Nasdaq
- News Gilead Sciences, Inc.
- Piper Sandler Lowers Gilead Sciences' Price Target to $100 From $105, Overweight Rating Kept